Online inquiry

IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11822MR)

This product GTTS-WQ11822MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11822MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9342MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ11445MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ14942MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ2135MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ9814MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ13856MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ6796MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ7355MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW